Breaking Ground Article by K. Kimberly McCleary, about the Research Institute Without Walls. We believe in the power of systematically exploring all drugs and mechanisms for their potential against any disease. We have used this idea as the driving force to create a technologic capability, COSS, that maps and ranks all drugs versus all diseases, side … Read More
News
Health Blog: With Help from Author Laura Hillenbrand, Drug Repurposing Comes to Chronic Fatigue Syndrome
Article by Health Blog’s Amy Dockser Marcus on Biovista’s contribution to CFS research. The CFIDS Association of America says that $2 million in funding — backed by individual gifts including a $250,000 donation from best-selling writer Laura Hillenbrand, who has chronic fatigue syndrome– is going to grants and projects designed to accelerate the development of … Read More
Repurposed drugs and your IP strategy
Using examples of drugs and companies, Dr Andreas Persidis gives tips on how to establish a systematic drug repositioning programme. Online article in the Managing Intellectual Property website. In the absence of productive internal R&D sufficient to support growth, current pharmaceutical IP strategies focus on acquiring smaller biotechs with promising assets to bolster larger pharma’s … Read More
Every drug deserves a second chance
Guest Commentary in Drug Discovery News (DDN) by Andreas Persidis September 2011 After many years of talking about it, the patent cliff is finally with us in a big way. Starting with Pfizer’s Lipitor this coming November, Big Pharma is projected to lose more than $60 billion in the next five to six years from … Read More
Drug Discovery & Development: New Life for Old Drugs
Saving time and money The resources required to bring a new drug to market are as well-known as they are staggering: upwards of $1.3 billion in costs, 10 to 15 years from target selection to approval, and an overall failure rate approaching 95%.